Grass Allergy Pill a First for US Sufferers

Wednesday, 02 Apr 2014 07:05 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
France's Stallergenes has received U.S. regulatory approval to sell the first immunotherapy pill against grass allergies in the world's biggest pharmaceutical market, sending its shares up 6 percent on Wednesday.
 
Stallergenes has said it sees a potential U.S. market of nearly 3 million patients that will eventually be worth $1 billion in annual sales for these types of drugs.
 
"That's very positive news as the group is considerably expanding its market," Gilbert Dupont analysts wrote in a note.
 
Oralair is a fast-dissolving tablet to be placed under the tongue that contains extracts from five types of grass pollen: sweet vernal, orchard, perennial rye, timothy and Kentucky bluegrass. It harnesses the immune system to alleviate allergies and is an alternative to current treatments that need to be injected.
 
Merck and Danish partner ALK Abello are also expected to launch their rival therapy Grastek in the United States this year. In December, both drugs received strong recommendations from outside advisers to the U.S. Food and Drug Administration (FDA).
 
Oralair was approved in the European Union in 2008 and is also sold in Canada, Australia and Russia for the treatment of grass pollen allergy. It generated revenue of 22.2 million euros ($30.5 million) in 2013, up 37 percent from 2012.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

New Fertility Treatment Cheaper, Effective

Wednesday, 22 Oct 2014 08:36 AM

A crucial part of conventional in vitro fertilization (IVF) -- the incubation of embryos in a laboratory dish -- can ins . . .

'Breakthrough' Peanut Allergy Treatment Hits Market

Wednesday, 22 Oct 2014 08:20 AM

French biotechfirm DBV Technologies - developer of what it says is a breakthrough treatment for peanut allergy sufferers . . .

Drugmakers to Join Forces to Make Millions of Ebola Vaccine Doses

Wednesday, 22 Oct 2014 08:11 AM

J J has simplified and fast-tracked its vaccine program in the light of the world's worst Ebola outbreak.
Leading d . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved